ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes place between September 9th-13thin Milan, Italy. The company has had four abstracts accepted for presentation by the conference review committee, details of which are below:
Investigating optimal sputum processing methods for active neutrophil elastase quantification – SESSION 353 TECHNIQUES IN BIOMARKER SELECTION – Oral Presentation (presenting author Dr Charlene Robb) – MONDAY, SEPTEMBER 11, 2017 14:45—16:45h
The Development of a Novel Immunoassay for the Quantification of Active Tryptase – CHRONIC AIRWAY DISEASE: MARKERS OF DISEASE IMPACT – Thematic Poster Session (presenting author Dr Timothy Ferguson) – TUESDAY, SEPTEMBER 12, 2017 12:50-14:40h
Development of a Novel Immunoassay for the Measurement of Active Plasmin in Patients with IPF – CHRONIC AIRWAY DISEASE: MARKERS OF DISEASE IMPACT – Thematic Poster Session (presenting author Dr Darragh McCafferty) – TUESDAY, SEPTEMBER 12, 2017 12:50-14:40h
Examining the specificity of an internally quenched fluorogenic substrate for neutrophil elastase – CHRONIC AIRWAY DISEASE: MARKERS OF DISEASE IMPACT – Thematic Poster Session (presenting author Dr Charlene Robb) – TUESDAY, SEPTEMBER 12, 2017 12:50-14:40h
Dr David Ribeiro, CEO of ProAxsis, said: “ERS is an international organisation that brings together physicians, healthcare professionals, scientists and other experts working in respiratory medicine from all over the World. ProAxsis is very pleased to have such strong scientific presence at this key event, which gives us the opportunity to raise awareness of the multiple diagnostic offerings the company has in development.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com
Related News
ProAxsis Limited (www.proaxsis.com) is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation …
Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the …
ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, …